The Effects of the Combination of Rhein and Platelet-Rich Plasma on Human Articular Chondrocytes.
chondrocytes
knee osteoarthritis
platelet-rich plasma
rhein
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
11 Aug 2023
11 Aug 2023
Historique:
received:
26
06
2023
revised:
24
07
2023
accepted:
09
08
2023
medline:
26
8
2023
pubmed:
26
8
2023
entrez:
26
8
2023
Statut:
epublish
Résumé
The presence of side effects and low bioavailability of rhein has limited its use in the treatment of osteoarthritis. We aimed to evaluate the in vitro response of human articular chondrocytes to the presence of the combination of platelet-rich plasma (PRP) and rhein. Solutions of rhein were prepared to assess solubility and select a working concentration. A stimulus with interleukin-1β (IL-β, 10 ng/mL) was induced for 24 h on human chondrocytes. Five treatment groups were established: control, IL-β control, PRP, rhein, and PRP + rhein. Cell viability, cell migration, nitric oxide (NO) production, tumor necrosis factor-α (TNF-α), and gene expression analyses were carried out. A concentration of 50 mg/L was selected after a dose-response curve assay. Both NO and tumor TNF-α production significantly decreased after PRP and PRP + rhein treatments at 24 and 48 h. The wound healing assay revealed a significant stimulation of migration after 72 h with the PRP and PRP + rhein treatments. Expression of IL-1β, IL-6, MMP-13, and ADAMTS-5 was significantly downregulated, particularly after treatment with the combination of PRP + rhein. Much of the determinations denoted a better performance of the combination of PRP and rhein in decreasing the levels of the different targets evaluated; however, this was not great enough to detect a significant difference in comparison with the PRP treatment alone.
Sections du résumé
BACKGROUND
BACKGROUND
The presence of side effects and low bioavailability of rhein has limited its use in the treatment of osteoarthritis. We aimed to evaluate the in vitro response of human articular chondrocytes to the presence of the combination of platelet-rich plasma (PRP) and rhein.
METHODS
METHODS
Solutions of rhein were prepared to assess solubility and select a working concentration. A stimulus with interleukin-1β (IL-β, 10 ng/mL) was induced for 24 h on human chondrocytes. Five treatment groups were established: control, IL-β control, PRP, rhein, and PRP + rhein. Cell viability, cell migration, nitric oxide (NO) production, tumor necrosis factor-α (TNF-α), and gene expression analyses were carried out.
RESULTS
RESULTS
A concentration of 50 mg/L was selected after a dose-response curve assay. Both NO and tumor TNF-α production significantly decreased after PRP and PRP + rhein treatments at 24 and 48 h. The wound healing assay revealed a significant stimulation of migration after 72 h with the PRP and PRP + rhein treatments. Expression of IL-1β, IL-6, MMP-13, and ADAMTS-5 was significantly downregulated, particularly after treatment with the combination of PRP + rhein.
CONCLUSIONS
CONCLUSIONS
Much of the determinations denoted a better performance of the combination of PRP and rhein in decreasing the levels of the different targets evaluated; however, this was not great enough to detect a significant difference in comparison with the PRP treatment alone.
Identifiants
pubmed: 37629580
pii: life13081723
doi: 10.3390/life13081723
pmc: PMC10455863
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Biomaterials. 2011 Sep;32(25):5847-54
pubmed: 21616530
Mol Med Rep. 2016 Nov;14(5):4075-4082
pubmed: 27665780
Osteoarthritis Cartilage. 2008;16 Suppl 2:S15-20
pubmed: 18794013
Am J Sports Med. 2011 Nov;39(11):2362-70
pubmed: 21856929
Am J Sports Med. 2015 Oct;43(10):2481-9
pubmed: 26306780
Mol Med Rep. 2017 May;15(5):2940-2948
pubmed: 28339078
Am J Chin Med. 2005;33(6):839-50
pubmed: 16355440
Tissue Cell. 2021 Dec;73:101646
pubmed: 34536814
Osteoarthritis Cartilage. 2006 Sep;14(9):839-48
pubmed: 16730463
Osteoarthritis Cartilage. 1999 May;7(3):272-80
pubmed: 10329302
Cell Adh Migr. 2014;8(5):440-51
pubmed: 25482647
Scand J Rheumatol. 2009 Mar-Apr;38(2):104-11
pubmed: 19274517
Arthroscopy. 2013 Aug;29(8):1399-409
pubmed: 23669235
Rheum Dis Clin North Am. 2022 Aug;48(3):637-657
pubmed: 35953228
J Orthop Surg Res. 2019 Dec 30;14(1):470
pubmed: 31888697
Lancet. 2015 Jul 25;386(9991):376-87
pubmed: 25748615
Curr Rheumatol Rev. 2022;18(1):20-32
pubmed: 34784876
Biomed Res Int. 2018 Jul 24;2018:9726703
pubmed: 30140705
Osteoarthritis Cartilage. 2000 May;8(3):186-96
pubmed: 10806046
Arthritis Rheumatol. 2020 Feb;72(2):220-233
pubmed: 31908163
Am J Sports Med. 2015 Jun;43(6):1467-73
pubmed: 25813869
Semin Arthritis Rheum. 2014 Dec;44(3):253-63
pubmed: 24953861
Mediators Inflamm. 2020 Mar 3;2020:8293921
pubmed: 32189997
PLoS One. 2020 Jul 28;15(7):e0232565
pubmed: 32722676
Biorheology. 2006;43(3,4):577-87
pubmed: 16912429
Rheumatology (Oxford). 2007 Dec;46(12):1769-72
pubmed: 17942474
Clin Exp Rheumatol. 2007 Jul-Aug;25(4):546-55
pubmed: 17888210
J Cell Biochem. 1998 Apr 1;69(1):19-29
pubmed: 9513043
Tissue Eng Part A. 2013 Jun;19(11-12):1476-88
pubmed: 23360471
Int J Mol Sci. 2021 Mar 01;22(5):
pubmed: 33804447
Presse Med. 2004 May 22;33(9 Pt 2):S10-2
pubmed: 15226683
Arthritis Care Res (Hoboken). 2013 May;65(5):703-11
pubmed: 23203864
J Sep Sci. 2012 Aug;35(16):2063-8
pubmed: 22753114
Biochem Pharmacol. 2003 Feb 1;65(3):377-88
pubmed: 12527330
Medicine (Baltimore). 2022 Nov 18;101(46):e31700
pubmed: 36401382
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
J Orthop Res. 2011 Sep;29(9):1320-6
pubmed: 21437966
Biomaterials. 2014 Dec;35(36):9599-607
pubmed: 25176059
Colloids Surf B Biointerfaces. 2021 Jun;202:111713
pubmed: 33780905
Int J Mol Sci. 2022 Jan 24;23(3):
pubmed: 35163225
Osteoarthritis Cartilage. 2001 Apr;9(3):257-63
pubmed: 11300749
Clin Pharmacokinet. 1998 Nov;35(5):347-59
pubmed: 9839088
J Vis Exp. 2014 Jun 01;(88):
pubmed: 24962652
Evid Based Complement Alternat Med. 2015;2015:578107
pubmed: 26185519
Curr Drug Deliv. 2016;13(1):83-9
pubmed: 26166151
J Rheumatol. 1998 Dec;25(12):2417-24
pubmed: 9858439
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Eur J Pharm Sci. 2017 Jan 1;96:390-397
pubmed: 27721042
Exp Cell Res. 2017 Mar 1;352(1):146-156
pubmed: 28202394
Int J Mol Sci. 2021 May 23;22(11):
pubmed: 34071037
J Bone Joint Surg Am. 2014 Mar 5;96(5):423-9
pubmed: 24599205
Bull World Health Organ. 2003;81(9):646-56
pubmed: 14710506
Drug Saf. 2015 Mar;38(3):245-52
pubmed: 25652235